
|Articles|October 5, 2010
Look for upcoming Practice & Policy in November edition of ONCOLOGY
Author(s)Michael Mccaughan
Second-Guessing FDA: CMS’ Expanding Regulatory Role
Advertisement
Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA’s jurisdiction-and the health care reform implementation is bringing more of those cases to the fore...
Check out the complete article by an award-winning journalist in the upcoming edition of ONCOLOGY...
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
How Did Daraxonrasib Double Survival in Pretreated Metastatic Pancreatic Cancer?
2
Tebentafusp Yields Favorable 5-Year OS Data in HLA-A*02:01+ Uveal Melanoma
3
Belantamab Mafodotin Combo for R/R Multiple Myeloma Earns Approval in China
4
Analyzing the Role of CELMoDs in the Relapsed/Refractory Myeloma Space
5

























































